reason report
reiter rate share increas former
price target per share near-term
outlook remain challeng reflect estim
revis note report secular outlook csi
remain favor potenti enhanc specif
stand benefit strong presenc across modal
materi channel misight repres potenti materi
long-term growth driver within emerg myopia control market
figur opportun likewis unrest caus
may prompt coupl delay famili plan increas demand
csi fertil offer long-term addit women potenti
seek perman non-hormon birth control option
increas price increas former
price target per share revis price target
impli multipl ebitda non-gaap
earn versu former price target base like
multipl respect
revis estim lower revenu
non-gaap earn estim see figur better reflect
headwind creat result lower
former revenu non-gaap earn estim
billion billion per share respect
likewis like conserv also moder former
billion revenu non-gaap earn
estim billion per share
thought valuat share current trade
ebitda non-gaap earn versu
industri peer trade like multipl respect
opinion favor recur natur busi
revenu coupl inelast demand major
csi portfolio minimum merit peer multipl valuat
moreov need vision care women health subject
materi swing due econom chang brought
pandem relat care use devic
gener occur non-acut care office-bas set posit
busi rebound sooner occur acut care
outpati surgeri set
cooper compani inc global compani
two busi unit coopervis
develop market comprehens rang
contact lens coopersurg csi
develop manufactur market medic
devic diagnost product surgic instrument
accessori women health marketplac
import disclosur analyst certif page report access current disclosur
stephen inc cover compani client may refer
updat thought misight take opportun updat publish view first publish
detail march see report domest myopia control market opportun misight potenti contribut
forward outlook specif estim market myopia control current estim approxim
million global use off-label solut limit efficaci potenti grow excess
billion domest moreov estim scale market penetr misight stand add
million revenu non-gaap earn see figur
focu pandem myopia current world popul myopic figur equival
billion individu within framework approxim million individu suffer high myopia
aforement popul forecast increas global popul impli
billion peopl suffer high myopia everi diopter matter note high myop statist
signific increas risk sight threaten diseas maculopathi retin detach poag posterior
chang annual estim take conserv postur revenu
non-gaap earn estim see figur reflect updat view end market trend follow
calendar earn season greater insight market implic pandem specif
reduc former revenu non-gaap earn estim billion billion
per share respect likewis revis former billion revenu
non-gaap earn estim billion per share
 assum declin declin led single-
use daili dispos sale growth modest million contribut misight versu prior assumpt
csi assum fertil ob/gyn end market declin combin fiscal fiscal
fiscal paragard sale declin yoy fertil declin
oper estim gross margin declin oper margin eas
remain
fiscal preview revis fiscal revenu non-gaap earn estim million
consensu respect quarter revenu estim million fall approxim
million consensu revis csi revenu estim million fall million consensu
likewis revis estim revenu non-gaap earn estim million
good sold cog
declin yoy new fit growth halt end market slow
assum macro ob/gyn fiscal
opex impact effect limit gm declin
note epidemiolog myopia diseas associ increas incid
stale consensu street rang
variou ocular comorbid vari sever
compani report stephen estim
million except per share data
consensu revenu non-gaap earn estim reflect
aggress revis appar stale expect
quarterli expect sale rang million
estim rang million
million except per share data
note epidemiolog myopia diseas associ increas incid
variou ocular comorbid vari sever
revis fiscal million consensu
revis million
myopia myopia refract error ray light enter eye parallel
optic axi brought focu front retina ocular accommod relax usual
result eyebal long front back commonli known
three stage myopia
pre-myopia refract state eye children
combin risk factor provid suffici likelihood futur develop myopia
myopia condit spheric equival refract error eye
ocular accommod relax
high myopia condit spheric equival refract error eye
ocular accommod relax
investig ophthalmolog vi feb american optometr associ
figur high myopia lead increas preval moder sever ocular complic
note epidemiolog myopia diseas associ increas incid
variou ocular comorbid vari sever
particular interest high myop increas axial length predispos
higher rate peripher retin chang degener retin detach dens
increas incid aforement result product loss
creat materi cost burden healthcar system
flitcroft di complex interact retin optic environment factor myopia aetiolog prog retin mitchel hourihan sandbach wang jj relationship
glaucoma myopia mountain studi ophthalmolog du cruickshank et al case-control studi stroke qualiti hypertens control north
west england bmj essilor america
figur north america preval myopia high myopia
preval rate myopia high myopia increas aggress pace
myopia affect north america popul begin earli childhood
adolesc progress adulthood estim impact
popul
beyond societ development ramif high myopia causal factor
increas preval costli sight-threaten ocular disord affect
north america popul estim reach
global preval myopia high myopia tempor trend brien holden dsc timothi frick david wilson phd monica jong phd kovin naidoo phd
figur global preval myopia high myopia
global perspect myopia affect approxim world popul
estim impact popul high myopia current
affect popul rate expect doubl
global preval myopia high myopia tempor trend brien holden dsc timothi frick david wilson phd monica jong phd kovin naidoo phd
use reshap
coo misight day daili wear contact lens repres fda approv treatment
slow progress myopia prescrib children year old
cooper compani american academi ophthalmolog amazon theeyepractic com
figur off-label solut lack data associ risk
posit wear
night need
glass day
associ
increas risk
cost atropin
photophobia blurri
near vision local
success unpredict
therapi diseas
posit easi
prescrib easi
young children wear
largest concern
relat peripher
altern coo misight lens first fda-approv contact len therapi
use myopia control children age year fda-approv studi misight therapi
demonstr reduct progress myopia children addit misight
comfort patient favor risk profil contact lens
stephen inc compani report american academi ophthalmolog managemyopia org
figur size domest opportun
preval high myopia
exist market off-label product myopic control could grow well
excess billion safe efficaci fda-approv therapi like
stephen inc estim unit state censu data compani report
figur increment upsid
provi incom tax
assum captur domest high myopic pediatr popul
misight price ecp channel impli increment million
equival increment annual sale growth
stephen inc estim million except per share data
revenu busi model
averag revenu
remain valu rel
discount compar industri
consolid gaap statement incom
million except per share data
fiscal period
fiscal period
fiscal period
good sold cog
 amort intang
compani file stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
